Volume 1 Issue 1
Jul.  2010
Turn off MathJax
Article Contents
Jing ZHANG, Zhi-yong LIANG, Jie GAO, Tong-hua LIU. Relationship between the Mutations of Epidermal Growth Factor Receptor Gene and k-ras Gene and the Clinicopathological Features of Non-small Cell Lung Cancers[J]. Medical Journal of Peking Union Medical College Hospital, 2010, 1(1): 53-59.
Citation: Jing ZHANG, Zhi-yong LIANG, Jie GAO, Tong-hua LIU. Relationship between the Mutations of Epidermal Growth Factor Receptor Gene and k-ras Gene and the Clinicopathological Features of Non-small Cell Lung Cancers[J]. Medical Journal of Peking Union Medical College Hospital, 2010, 1(1): 53-59.

Relationship between the Mutations of Epidermal Growth Factor Receptor Gene and k-ras Gene and the Clinicopathological Features of Non-small Cell Lung Cancers

More Information
  • Corresponding author: LU Tong-hua Tel: 010-65295523, E-mail:liuth_pumch@yahoo.com.cn
  • Received Date: 2010-06-24
  • Publish Date: 2010-07-30
  •   Objective  To investigate the relationship between the mutations of epidermal growth factor receptor(EGFR)gene, k-ras gene and clinicopathological characteristics in Chinese patients with non-small cell lung cancers (NSCLC).  Methods  Tumor cells were collected by microdissection from paraffin embedded tumor specimens obtained from 170 patients with NSCLC. The genomic DNA was extracted.Mutations of EGFR gene (exons 18, 19, 20, and 21) and k-ras gene (codons 12 and 13) were detected by scorpions amplification refractory mutation system (Scorpions ARMS).  Results  Somatic mutations were identified involving the tyrosine kinase domain of the EGFR gene in 84 patients (49.4%), which included in-frame deletions of exon 19 (n=39), point mutation of exon 21L858R (n=34), point mutation of exon 21L861Q (n=3), insertions mutations (n=4) and point mutation in exon 20 (n=2), and co-existence of T790M point mutation in exon 20 and L858R point mutations in exon 21 (n=2). k-ras mutations were identified in 14 patients (8.2%), among whom a single-amino-acid substitution in codon 12 were noted in all of them including 8 for 12CYS, 3 for 12ASP, and 3 for 12VAL. Simultaneously harbored EGFR and k-ras gene mutations were not observed in any single NSCLC specimen. Compared adenocarcinoma with non-adenocarcinoma, EGFR mutation rate was statistically significant (P < 0.001) and the former had higher mutation rate. Also, the relationship between EGFR mutations and various clinicopathological factors suggested that the EGFR mutations usually occurred in the female, non-smokers, smaller tumors (≤ 3 cm), and better differentiation. However, there was no association among age, gender, smoking, tumor size, histological types, differentiation grades, lymph node metastasis, pTNM stages and k-ras mutations (P > 0.05).  Conclusions  The detection rate of EGFR mutation is remarkably higher in China than other countries, especially in non-smoking female patients with adenocarcinoma. The detection rate of k-ras mutation is very low, which is not associated with the clinical features such as gender and age. The efficacy and drug resistance of gefitinib is associated with the mutations of EGFR and k-ras gene. k-ras mutations does not coexist with EGFR mutations. Scorpions ARMS method is a rapid, sensitive, and accurate technology in detecting the mutations of EGFR gene and k-ras gene and can therefore provide useful information for clinical decision-making.
  • loading
  • [1] Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organization classification of tumors.Pathology and genetics tumors of the lung, plrura, thymus and heart [M].Lyon:IARC Press, 2004:12-15.
    [2] Jemal A, Siegel R, Ward E, et al.Cancer Statistics, 2006 [J].CA Cancer J Clin, 2006, 56:106-130. doi:  10.3322/canjclin.56.2.106
    [3] Scagliotti GV, Selvaggi G, Novello S, et al.The biology of epidermal growth factor receptor in lung cancer[J].Clin Cancer Res, 2004, 10:4227-4232. doi:  10.1158/1078-0432.CCR-040007
    [4] Fukuoka M, Yano S, Giaccone G, et al.Multiinstitutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer[J].J Clin Oncol, 2003, 21:2237-2246. doi:  10.1200/JCO.2003.10.038
    [5] Kris MG, Natale RB, Herbst RS, et al.Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer:a randomized trial[J].JAMA, 2003, 290: 2149-2158. doi:  10.1001/jama.290.16.2149
    [6] Paez JG, Janne PA, Lee JC, et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy [J].Science, 2004, 304:1497-1500. doi:  10.1126/science.1099314
    [7] Lynch TJ, Bell DW, Sordella R, et al.Activating mutations in the epidermal growth factor recepto runderlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med, 2004, 350:2129-2139. doi:  10.1056/NEJMoa040938
    [8] Shigematsu H, Lin L, Takahashi T, et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J].J Natl Cancer Inst, 2005, 97:339-346. doi:  10.1093/jnci/dji055
    [9] 张静, 梁智勇, 曾瑄, 等.应用蝎形探针扩增阻滞突变系统检测非小细胞肺癌表皮生长因子受体基因突变与病理改变的关系[J].中华病理学杂志, 2008, 37:294- 299. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhblx200805002
    [10] Graziano SL, Gamble GP, Newman NB, et al.Prognostic significance of k-rascodon 12 mutations in patients with resected stage Ⅰ and Ⅱ non-small-cell lung cancer[J].J Clin Oncol, 1999, 17:668-675. doi:  10.1200/JCO.1999.17.2.668
    [11] Massarelli E, Varella-Garcia M, Tang X, et al.KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J].Clin Cancer Res, 2007, 13:2890-2896. doi:  10.1158/1078-0432.CCR-06-3043
    [12] Fujno S, Enokibori T, Tezuka N, et al.A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer[J].Eur J Cancer, 1996, 32A, 2070-2074. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1097/CJI.0000000000000300
    [13] Bell DW, Lynch TJ, Haserlat SM, et al.Epidermal growth factor receptor mutations and gene amplification in nonsmall-cell lung cancer:molecular analysis of the IDEAL/INTACT gefitinib trials[J].J Clin Oncol, 2005, 23:8081- 8092. doi:  10.1200/JCO.2005.02.7078
    [14] Masaki T, Shiniehi T, Katsuyuki K, et al.The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non small cell lung cancers[J]. Clin Cancer Res, 2005, 11:1167-1173. http://jjco.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=clincanres&resid=11/3/1167
    [15] 张晓彤, 李龙芸, 王树兰, 等.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志, 2005, 28:180-183. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhjhhhx200503010
    [16] Sanford M, Scott LJ.Gefitinib:a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer[J].Drugs, 2009, 69:2303-2328. doi:  10.2165/10489100-000000000-00000
    [17] Kalikaki A, Koutsopoulos A, Hatzidaki D, et al.Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and k-ras mutation status[J].Lung Cancer, 2010, 69:110-115. doi:  10.1016/j.lungcan.2009.09.010
    [18] Slebos RJ, Kibbelaar RE, Dalesio O, et al.k-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung[J].N Engl J Med, 1990, 323:561-565. doi:  10.1056/NEJM199008303230902
    [19] Massarelli E, Varella-Garcia M, Tang X, et al.KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J].Clin Cancer Res, 2007, 13:2890-2896. doi:  10.1158/1078-0432.CCR-06-3043
    [20] Linardou H, Dahabreh IJ, Kanaloupiti D, et al.Assessment of somatic k-ras mutations as a mechanism associated with resistance to EGFR-targeted agents:a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer[J].Lancet Oncol, 2008, 9:962-972. doi:  10.1016/S1470-2045(08)70206-7
    [21] Kosaka T, Yatabe Y, Endoh H, et al.Mutations of the epidermal growth factor receptor gene in lung cancer:biological and clinical implications[J]. Cancer Res, 2004, 64: 8919-8923. doi:  10.1158/0008-5472.CAN-04-2818
    [22] Planchard D, Loriot Y, Besse B.Impac t of KRAS in standard treatment of non-smallcell lung cancer(NSCLC) patients in 2009:prognostic and predictive value[J].Bull Cancer, 2009, 96:S57-S68.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(6)  / Tables(1)

    Article Metrics

    Article views (215) PDF downloads(20) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return